Evidence map›Paper›PMID 32121014›Full record

ReviewCells2020

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.

Andrew M K Law, Fatima Valdes-Mora, David Gallego-Ortega

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05910034 (The Study of Envafolimab Plus Docetaxel in Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC Previously Treated With a PD-1 Inhibitor Combined With Chemotherapy), which is not on this map. Cited by 291 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
291citing papers in PubMed, 3 pooled it
25.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05910034 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

The Study of Envafolimab Plus Docetaxel in Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC Previously Treated With a PD-1 Inhibitor Combined With Chemotherapy

TypeinterventionalSponsorFudan UniversityRan2023 to 2026Enrolled132ConditionsAdvanced Non-Small Cell Lung CancerArmsTrilaciclib+Envafolimab+Docetaxel, Envafolimab+Docetaxel, Docetaxel
3 · Its place in the literature

Who cites it

291 citing papers in PubMed, 3 syntheses or guidelines pooled it, 449 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

231 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Andrew M K LawTumour Development Group, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 2010 Sydney NSW, Australia.
Fatima Valdes-MoraHistone Variants Group, Garvan Institute of Medical Research, 2010 Sydney NSW, Australia.
David Gallego-OrtegaTumour Development Group, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 2010 Sydney NSW, Australia.
Garvan Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of immunotherapy has been an astounding breakthrough in cancer treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have shown remarkable therapeutic outcomes. However, response rates from immunotherapy have been reported to be varied, with some having pronounced success and others with minimal to no clinical benefit. An important aspect associated with this discrepancy in patient response is the immune-suppressive effects elicited by the tumour microenvironment (TME). Immune suppression plays a pivotal role in regulating cancer progression, metastasis, and reducing immunotherapy success. Most notably, myeloid-derived suppressor cells (MDSC), a heterogeneous population of immature myeloid cells, have potent mechanisms to inhibit T-cell and NK-cell activity to promote tumour growth, development of the pre-metastatic niche, and contribute to resistance to immunotherapy. Accumulating research indicates that MDSC can be a therapeutic target to alleviate their pro-tumourigenic functions and immunosuppressive activities to bolster the efficacy of checkpoint inhibitors. In this review, we provide an overview of the general immunotherapeutic approaches and discuss the characterisation, expansion, and activities of MDSCs with the current treatments used to target them either as a single therapeutic target or synergistically in combination with immunotherapy.

Indexed as

AnimalsCarcinogenesisHumansImmune Checkpoint InhibitorsImmunosuppression TherapyImmunotherapyMyeloid-Derived Suppressor CellsNeoplasmsImmune Checkpoint Inhibitorsimmune checkpoint inhibitorsimmune systemimmunotherapyMyeloid derived suppressor cellstumour microenvironment

Identifiers

PMID32121014
PMCPMC7140518
OpenAlexW3010011098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.